Tessella » clinical-trials

DIA 23rd Annual Euro Meeting 2011; March 28-30th, 2011, Geneva, Switzerland

teac — Thu, 10 Mar 2011 11:43:59 +0000

Tessella’s Tom Parke, Head of Clinical Technologies, will be holding three separate talks at the DIA 23rd Annual Euro Meeting, taking place on March 28-30th, 2011, Geneva, Switzerland.

Tom’s topics are:

Incorporating biomarker data in clinical trials for developing personalised medicine
Commercial Software Solutions for Exploratory Studies
Using simulations to communicate the expected consequences of planned statistical analyses

To find out more about Tom’s sessions or about this event and how to register online, visit http://www.diahome.org

The Telegraph: Drug and cosmetics firms back plan to cut animal testing

teac — Mon, 29 Nov 2010 14:20:02 +0000

Today The Telegraph published an article about drug and cosmetic firms planning to cut back on animal testing, click here to see full article. The time is right for a big push in this area with affordable computing power, sophisticated computer models based on many years’ experience and huge quantities of experimental data now all available. Success will come from understanding all three components and bringing them all together, which is where Tessella has a major role to play.

2010 Accelrys European User Group Meeting; October 26-28th, Barcelona, Spain

teac — Tue, 14 Sep 2010 10:13:21 +0000

Tessella are sponsoring this year’s 2010 Accelrys European User Group Meeting, taking place at the Dolce Sitges Hotel in Barcelona, Spain on October 26-28th 2010.

Mark Roberts from Tessella and Ed Ainscow from AstraZeneca will be speaking at the event. The title of their abstract is ‘A Flexible Platform for Processing High-Content Screening Data’ which will focus on how Pipeline Pilot has been used to implement a highly flexible platform for processing high-content data.

To find out more or to register online visit www.accelrys.com

Webinar 8th June: FDA guidance on adaptive design – what does it mean for you?

fowj — Wed, 12 May 2010 14:20:01 +0000

Register for our live webcast on Tuesday, 8 June 2010

08:00 (PDT) 11:00 (EDT) 16:00 (BST) 17:00 (CEST)

Join Tom Parke as he quizzes adaptive trial gurus Prof. Don Berry and Dr. Scott Berry on the implications of the recent FDA Guidance on Adaptive Design for Clinical Trials. Tom will be getting answers to the key questions the guidance raises, namely:

What are the major conclusions of the guidance?
How does the guidance affect the future of clinical design?
Is it positive or negative for adaptive designs?
What role does Bayesian play in the guidance…if any?
What role, if any does simulation play in the guidance?
Why has Phase III been so clearly differentiated from earlier phases in the guidance?

FACTS User Group Meeting 2010 – July 20th – 21st, Cambridge, Massachusetts, USA

teac — Wed, 12 May 2010 13:22:16 +0000

The FACTS User Group Meeting will be taking place on July 20th and 21st 2010 at Le Meridien, Cambridge, Massachusetts, USA.

For further information about this event, please email info@tessella.com.

For information about FACTS and clinical trial solutions, visit www.smarterclinicaltrials.com

New Scientist: Personalised cancer trial promises better drugs faster

teac — Fri, 19 Mar 2010 10:10:09 +0000

Major changes to the way cancer drugs are tested in people could lead to better and cheaper therapies coming to the market more quickly…read more

Tessella and Berry Consultants team to deliver smarter clinical trials

fowj — Tue, 09 Feb 2010 09:55:20 +0000

Faced with the challenge of falling success rates in drug development, clinical development teams must find new ways forward. Tessella and Berry Consultants believe that designing smarter clinical trials is part of the solution. We believe that better trial design can help:
• Maximize the impact of your clinical trials on your drug development process.
• Ensure your trial answers the right questions about your compound, cost-effectively and on time.
• Apply sophisticated trial design techniques with total confidence.
Find out more at our new website www.smarterclinicaltrials.com

Abbott’s Yili Pritchett shares adaptive trial results at SMi’s Adaptive Designs in Clinical Drug Development Conference

fowj — Mon, 08 Feb 2010 18:21:44 +0000

Yili Pritchett of Abbott was able to show real data from a trial we ran for them between 2007-2009. Read more.

I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

fowj — Fri, 08 Jan 2010 08:26:36 +0000

The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators of response (tumor analysis prior to surgery via magnetic resonance imaging (MRI) images along with tissue and blood samples) are predictors of treatment success. More…

Researchers mobilizing global resources to test new treatments for severe H1N1 infection

fowj — Fri, 13 Nov 2009 12:13:56 +0000

Quick ‘bench-to-bedside’ clinical trial would enroll 1,400 influenza patients to test corticosteroids and statins as potential treatments

TORONTO, Ont., November 10, 2009 — An important, ground-breaking initiative is unfolding in the global critical care community in response to the H1N1 pandemic. Read more ….